Sumary of Keep some pandemic-initiated changes to cancer clinical trials, task force members urge:
- Please see the article for all other authors’ relevant financial disclosures.
- Back to Healio Some changes to cancer clinical trials instituted during the COVID-19 pandemic should have a permanent place in oncology research, according to an article published in Cancer Discovery.
- Adaptations the authors highlighted include increased remote consenting and telemedicine, use of alternative laboratories and imaging centers, investigational drug delivery, the administration of IV investigational drugs at the patient’s home or local clinic, and commercial attainment of study drugs approved for other indications.
- Flaherty, MD, director of clinical research at Massachusetts General Hospital Cancer Center, professor of medicine at Harvard Medical School, and member of the American Association for Cancer Research board of directors, told Healio.
- Flaherty Flaherty and fellow authors, who included leaders in government and industry on the AACR COVID-19 Task Force, wrote that the pandemic forced the medical community to reevaluate procedures that had long been standard practice in oncology clinical trials.
- The authors focused on adaptations among four key constituents: academic centers, industry sponsors, government-sponsored clinical trials and regulatory agency oversight.
- Recommendations in the authors’ “post-COVID-19 roadmap” for clinical trial conduct include: making electronic remote consenting permanent;
- allowing use of any laboratory and imaging center that meets specifications;